RxDoctor Payments Data

Richard Fair, MD

Anesthesiology · Shreveport, LANPI 1508144296

Payments from drug & device makers

What this record shows

This record is dominated by grants: $13,333 of the $16,804 with a category attached, or 79.3%. Medtronic accounts for 65.9% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $12,258 and has fallen 96.9% since, to $377 in 2025. Among anesthesiology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,804in general payments, 2019–2025

Across 76 payments — averaging $221.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$11K
  • Boston Scientific$5K
  • Saluda Medical Americas, Inc.$264
  • Nevro Corp.$172
  • Collegium Pharmaceutical, Inc.$155
  • Pacira Pharmaceuticals Incorporated$25
  • plus $55 from 3 others

What the payments were for

  • Grants$13,33379%
  • Travel & lodging$1,5889%
  • Food & beverage$1,88311%

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,804 in reported general payments places this provider in the 95th percentile of 497 anesthesiology providers in Louisiana.

See all anesthesiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$251,102
Medicare patients
577
Services billed
3,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl52$43,680
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen291$32,115
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen812$26,107
Buprenorphine64$19,522
BelsomraSuvorexant29$12,747
Xtampza ErOxycodone Myristate23$11,885
MovantikNaloxegol Oxalate20$8,034
LinzessLinaclotide11$5,809
Oxycodone Hcl220$4,724
Gabapentin237$3,965
Lidocaine46$3,964
Pregabalin166$2,493
Morphine Sulfate ErMorphine Sulfate83$1,961
Tizanidine Hcl148$1,494
Cyclobenzaprine Hcl110$1,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$155$55,56475 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 497 anesthesiology providers in Louisiana.

Other anesthesiology in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →